Skip to content
10-Q

Quarterly Report

BRIACELL THERAPEUTICS CORP. BCTX BCTXL BCTXZ

0001641172-25-015265

← back to feed
Filed
Jun 16, 2025 12:00 AM ET
Period of report
Restated figures. One or more values in this filing restate previously reported amounts.

On SEC.gov

Financials in this filing

Metric Period Value
Shares Outstanding Q3 2025 · Jun 16, 2025 6.78M sh
Cash And Equivalents Q3 2025 · Apr 30, 2025 $12.46M
Cash And Equivalents Q3 2025 · Jul 31, 2024 $862.09K
Current Liabilities Q3 2025 · Apr 30, 2025 $4.33M
Current Liabilities Q3 2025 · Jul 31, 2024 $7.46M
Current Assets Q3 2025 · Apr 30, 2025 $14.79M
Current Assets Q3 2025 · Jul 31, 2024 $3.65M
Total Assets Q3 2025 · Apr 30, 2025 $17M
Total Assets Q3 2025 · Jul 31, 2024 $5.87M
Shares Diluted restated Q3 2025 · Apr 30, 2024 1.07M sh
Shares Diluted restated Q3 2025 · Apr 30, 2024 1.07M sh
Operating Cash Flow Q3 2025 · Apr 30, 2024 −$20.09M
Eps Diluted restated Q3 2025 · Apr 30, 2024 $1.61
Eps Diluted restated Q3 2025 · Apr 30, 2024 −$3.36
Eps Basic restated Q3 2025 · Apr 30, 2024 $1.61
Eps Basic restated Q3 2025 · Apr 30, 2024 −$3.36
Sga Expense Q3 2025 · Apr 30, 2024 $1.57M
Sga Expense Q3 2025 · Apr 30, 2024 $4.79M
Rd Expense Q3 2025 · Apr 30, 2024 $7.66M
Rd Expense Q3 2025 · Apr 30, 2024 $22.77M
Net Income Q3 2025 · Apr 30, 2024 $1.72M
Net Income Q3 2025 · Apr 30, 2024 −$3.58M
Operating Income Q3 2025 · Apr 30, 2024 −$9.23M
Operating Income Q3 2025 · Apr 30, 2024 −$27.56M